A Study to Learn How Different Amounts of the Study Medicine Called PF-07314470 Are Tolerated and Act in the Body in Healthy Adults
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 1
Status
Terminated
Study type
Interventional
Design
Randomized · Triple · Other
Enrollment
23actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
The Sponsor has decided to terminate the above referenced clinical study for business reasons. There were no safety concerns that led to this decision and there was no impact to participant safety.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-02-11 | actual | When the study began enrolling |
| Primary completion | 2025-08-18 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-08-18 | actual | The whole study's end, after follow-up |
| First posted | 2025-02-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy
Interventions
- Biological: PF-07314470
- Biological: Placebo for PF-07314470
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants with Treatment Emergent Adverse Events Following Single Doses
measured Day 1 up to approximately Day 35
Number of Participants with Clinically Significant Change from Baseline in Laboratory Values Following Single Doses
measured Baseline up to approximately Day 35
Number of Participants with Clinically Significant Change from Baseline in Vital Signs Following Single Doses
measured Baseline up to approximately Day 35
Number of Participants with Clinically Significant Change from Baseline in ECGs Following Single Doses
measured Baseline up to approximately Day 35
Number of Participants with Treatment Emergent Adverse Events Following Multiple Doses
measured Day 1 up to approximately Day 64
Number of Participants with Clinically Significant Change from Baseline in Laboratory Values Following Multiple Doses
measured Baseline up to approximately Day 64
Number of Participants with Clinically Significant Change from Baseline in Vital Signs Following Multiple Doses
measured Baseline up to approximately Day 64
Number of Participants with Clinically Significant Change from Baseline in ECGs Following Multiple Doses
measured Baseline up to approximately Day 64
Number of Participants with Serious Adverse Events Following Single Doses
measured Day 1 up to approximately Day 35
Number of Participants with Serious Adverse Events Following Multiple Doses
measured Day 1 up to approximately Day 64
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed